51679-85-7

Usage

Uses

Used in Pharmaceutical Synthesis:
2-[ethoxy(oxo)acetyl]aminobenzoic acid is utilized as an intermediate in the synthesis of various pharmaceuticals and organic compounds. Its reactivity and ability to form new chemical bonds make it a valuable component in the creation of diverse medicinal agents.
Used in Anti-inflammatory and Analgesic Applications:
In the medical field, 2-[ethoxy(oxo)acetyl]aminobenzoic acid is used as an anti-inflammatory and analgesic agent. Its inherent properties allow it to potentially alleviate pain and reduce inflammation, making it a candidate for the development of new drugs aimed at treating conditions that involve these symptoms.
Used in Chemical Reactions:
Due to its reactivity, 2-[ethoxy(oxo)acetyl]aminobenzoic acid is employed in a variety of chemical reactions across different industries. Its capacity to form new bonds is particularly useful in the synthesis of complex organic molecules and other specialty chemicals.

InChI:InChI=1/C11H11NO5/c1-2-17-11(16)9(13)12-8-6-4-3-5-7(8)10(14)15/h3-6H,2H2,1H3,(H,12,13)(H,14,15)

Upstream product

• 144-62-7 oxalic acid 
• 118-92-3 anthranilic acid 
• 95-92-1 oxalic acid diethyl ester 
• 70258-72-9 2-ethoxycarbonyl-1,2-dihydroindol-3-one 
• 18631-77-1 2-hydroxy-3-oxo-2,3-dihydro-indole-2-carboxylic acid ethyl ester 
• 617-36-7 Ethyl oxamate 
• 4755-77-5 Ethyl oxalyl chloride 

Downstream Products

• 72426-19-8 2-[(5-amino-[1,3,4]thiadiazole-2-sulfonylaminooxalyl)-amino]-benzoic acid 
• 76508-91-3 2-{[(1R,2R)-2-Hydroxy-1-hydroxymethyl-2-(4-nitro-phenyl)-ethylaminooxalyl]-amino}-benzoic acid 
• 76508-91-3 2-{[(1S,2S)-2-Hydroxy-1-hydroxymethyl-2-(4-nitro-phenyl)-ethylaminooxalyl]-amino}-benzoic acid 
• 64-17-5 ethanol 
• 144-62-7 oxalic acid 
• 118-92-3 anthranilic acid 
• 5651-01-4 2-(oxalamino)benzoic acid 
• 51679-96-0 N₁-(2-carboxyphenyl)-N₂-(2-hydroxyethyl)oxalamide 
• 67472-16-6 2-(Hydroxyaminooxalyl-amino)-benzoic acid 
• 72117-60-3 2-Carboxyoxanilic acid hydrazide 

Relevant academic research and scientific papers

Synthesis and structure of a 1-D copper(II) coordination polymer bridged both by oxamido and carboxylate: In vitro anticancer activity and reactivity toward DNA and protein BSA

A 1-D copper(II) coordination polymer formulated as {[Cu2(bdpox)(dabt)](NO3)?H2O}n, where H3bdpox and dabt denote N-benzoate-N'-[3-(diethylamino)propyl]oxamide and 2,2'-diamino-4,4'-bithiazole, respec

A homometallic ferrimagnet based on mixed antiferromagnetic and ferromagnetic interactions through oxamato and carboxylato bridges

Two novel coordination polymers (CPs), {Cu[Cu(L)(H2O)-(py)] 2}n (1) and {Cu[Cu(L)(MeOH)]2·2H 2O}n (2), were synthesized using 2-(oxaloamino)benzoic acid (H3L) providing oxamate and carboxylate groups, and magnetically characterized. Different 2-D layer structures were formed based on oxamato-bridged tricopper units bridging via the carboxylate group. In compound 1, a simple antiferromagnetic interaction operates through the oxamato bridge in the tricopper core, whereas, 2 showed a tendency for ferrimagnetic ordering at 2 K, resulting from mixed antiferromagnetic and ferromagnetic interactions through oxamato and syn-anti-type carboxylato bridges. Copyright

Guanidinum chloride as dehydrocyclization agent in the synthesis of 2-fuctionalized (4H)-3,1-benzoxazine-4-ones

A facile and expedient route for the synthesis of 2-ethoxy- and 2-(ethylcarboxylate)-(4H)-3,1-benzoxazine-4-ones is described using guanidinium chloride as a safe and convenient dehydrocyclization agent. High yields of the products obtain under mild react

From a dissymmetrical oxamidate ligand to a 2D coordination polymer: Synthesis, crystal structure and magnetic properties

A new dissymmetrical oxamidate ligand has been used to construct a metal-organic network. Using this ligand, a novel coordination polymer, namely {[Cu(obea)]2Cu.CH3OH.H2O}n (1) [H3obea = N1-(2-carboxyphenyl)-N2-(2-hydroxyethyl)oxalamide] has been synthesized and characterized by single-crystal X-ray analysis. The structure of complex 1 consists of neutral trinuclear complex units. Through syn-anti carboxylate bridges, the complex features a 2D structure with a helical substructure. Its magnetic properties have been investigated.

Reactions of ethyl oxamate and dialkyl oxalates with anthranilic acid derivatives

Ethyl oxamate reacted with anthranilic acid derivatives at the amide or the ester group leading to the formation of respective esters or amides. A simple method was developed for preparation of alkyl 3-amino-4-oxo-3,4- dihydroquinazoline-2-carboxylates. Nauka/Interperiodica 2007.

Discovery and SAR of a novel selective and orally bioavailable nonpeptide classical competitive inhibitor class of protein-tyrosine phosphatase 1B

Reversible phosphorylation and dephosphorylation of key proteins on tyrosine residues are important parts of intracellular signaling triggered by hormones and other agents. Recent knock-out studies in mice have identified PTP1B as a potential target for t

Modulators of protein tyrosine phosphatases (PTPases)

The present invention provides novel compounds of Formula 1, compositions containing these compounds, methods of their use, and methods of their manufacture, where such compounds are pharmacologically useful inhibitors of Protein Tyrosine Phosphatases (PTPase's) such as PTP1B, CD45, SHP-1, SHP-2, PTPα, LAR and HePTP or the like, wherein A, R1, R2, R3, R4, R16and R17are as defined in the specification. The compounds are useful in the treatment of type I diabetes, type II diabetes, impaired glucose tolerance, insulin resistance, obesity, immune dysfunctions including autoimmunity diseases with dysfunctions of the coagulation system, allergic diseases including asthma, osteoporosis, proliferative disorders including cancer and psoriasis, diseases with decreased or increased synthesis or effects of growth hormone, diseases with decreased or increased synthesis of hormones or cytokines that regulate the release of/or response to growth hormone, diseases of the brain including Alzheimer's disease and schizophrenia, and infectious diseases.

Oxamic acid derivatives

Anti-allergic agents of aromatic oxamic acid derivation present the following formula: STR1 in which A is a member selected from the group consisting of α-naphthyl, β-napthtyl, phenyl, 2,6-di-chlorophenyl, and substituted phenyl moieties containing from one to three substituents in any of the 2,3,4 and 5 positions of the phenyl ring, independently selected from the group consisting of lower alkyl, lower alkylthio, lower alkylsulfinyl, lower alkoxy, hydroxy (lower)alkoxy, 2-(oxalyloxy) ethoxy, benzyloxy, N-mono- and di-lower alkylamino(lower)alkoxy, halo, sulfamyl, polyhalo(lower)alkyl, carbamyl, N-lower alkylcarbamyl, nitro, mono and di lower alkylamino, carboxy, lower alkylcarbonyl, carb(lower)alkoxy, phenoxy(lower)alkoxy, and oxalamidophenoxy radicals; and pharmaceutically acceptable salts thereof.

Oxamic acid derivatives

Anti-allergic agents of aromatic and heterocyclic oxamic acid derivation present the following formula: STR1 in which A is a member selected from the group consisting of 2-thiazolyl, 2-pyridyl, 2-pyridyl-N-oxide, 6-(lower)alkyl-2-pyridyl, 3-cyano-2-pyridyl, 3-pyridyl, 4-pyridyl, 2-pyrimidinyl, 2-pyrazinyl, α-naphthyl, β-naphthyl, phenyl, 2,6-di-chlorophenyl, and substituted phenyl moieties containing from one to three substituents in any of the 2,3,4 and 5 positions of the phenyl ring, independently selected from the group consisting of lower alkyl, lower alkylthio, lower alkylsulfinyl, lower alkoxy, hydroxy(lower)alkoxy, 2-(lower alkoxy oxalyloxy) ethoxy, benzyloxy, N-mono-and di-lower alkylamino(lower)alkoxy, halo, sulfamyl, polyhalo(lower)alkyl, carbamyl, N-lower alkylcarbamyl, nitro, mono-and di-lower alkylamino, phenylazo, carboxy, lower alkylcarbonyl, cyano, carb(lower)alkoxy, phenoxy(lower)alkoxy, lower alkoxyoxalamido and lower alkoxyoxalamidophenoxy radicals; B, when taken alone, is a member selected from the group consisting of --OH, lower alkoxy, --NH2, --NHOH, cyclohexyloxy and phenoxy; and Y is a member selected from the group consisting of oxygen and when taken with B and the carbon atom to which they are attached, forms the moiety STR2

Oxamic acid derivatives

Anti-allergic agents of aromatic oxamic acid derivation present the following formula: STR1 in which A is a member selected from the group consisting of α-naphthyl, β-naphthyl, phenyl, 2,6-di-chlorophenyl, and substituted phenyl moieties containing from one to three substituents in any of the 2,3,4 and 5 positions of the phenyl ring, independently selected from the group consisting of lower alkyl, lower alkylthio, lower alkylsulfinyl, lower alkoxy, hydroxy (lower)alkoxy, 2-(oxalyloxy) ethoxy, benzyloxy, N-mono- and di-lower alkylamino(lower)alkoxy, halo, sulfamyl, polyhalo(lower)alkyl, carbamyl, N-lower alkylcarbamyl, nitro, mono and di lower alkylamino, carboxy, lower alkylcarbonyl, carb(lower)alkoxy, phenoxy(lower)alkoxy, and oxalamidophenoxy radicals; And pharmaceutically acceptable salts thereof.